The board of directors of Sihuan Pharmaceutical Holdings Group Ltd. announced that, Proline Janagliflozin tablets (Trade Name: Huiyoujing, a sodium glucose transporter 2 inhibitor ("SGLT-2 inhibitor") and national Class 1 innovative drug, developed by Huisheng Biopharmaceutical Co. Ltd. (Huisheng Biopharmaceutical), a non-wholly owned subsidiary of the Group, has obtained drug registration approval from the National Medical Products Administration (the "NMPA") of the People's Republic of China (China) for the treatment of type 2 diabetes. This will be the second self-developed SGLT-2 inhibitor innovative drug approved and marketed in China, which marks the breakthrough progress of Huisheng Biopharmaceutical in the research and development of innovative drugs in the field of diabetes treatment.

The SGLT-2 inhibitor is a new type of oral hypoglycemic drug highly recommended internationally for the treatment of patients with type 2 diabetes mellitus. It selectively inhibits the SGLT-2 receptor in renal proximal tubules, to reduce glucose re-absorption and promote urinary glucose excretion, thus lowering blood glucose concentration. SGLT-2 inhibitors not only have good hypoglycemic effect, but also have multiple benefits such as cardiovascular and renal protection, which is recommended by domestic and foreign guidelines in multiple fields, and also have the potential to expand to cardiovascular disease, chronic kidney disease and other indications.

Janagliflozin, as a SGLT-2 inhibitor, is a national Class 1 innovative drug, and its phase III clinical data showed that it not only has significant hypoglycemic efficacy (the decrease of HbA1c is up to 1.4% compared to baseline), but also has multiple benefits such as lowering blood pressure, reducing weight and improving blood lipids, etc., with low risk of hypoglycemia, and good overall safety. When compared side-by-side with phase III clinical data of similar SGLT-2 inhibitor products already on the market, Janagliflozin showed similar or even better results. Huisheng Biopharmaceutical owns the patent rights of Janagliflozin in multiple countries and regions including China, the United States, Europe, Japan, South Korea and Hong Kong, etc.